About 18 results found for searched term "B-Raf inhibitor 1" (0.124 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M9492 | B-Raf inhibitor 1 | Raf |
| ABM-0403 | ||
| B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor with cell IC50s of 0.31 µM and 2 nM for A375 proliferation and A375 p-ERK, respectively. | ||
| M20688 | B-Raf inhibitor 1 (Compound 13) dihydrochloride | Raf |
| B-Raf inhibitor 1 (Compound 13) is a type IIA Raf inhibitor which bind to the DFG-out conformation with ki of 1 nM,1 nM,and 0.3 nM for B-Raf(WT), B-Raf(V600E) and C-Raf, respectively. | ||
| M1774 | PLX-4720 | Raf |
| PLX4720 | ||
| PLX-4720 is a selective BRAFV600E inhibitor with the IC50 values of 160 nM and 130 nM for B-Raf and BRK respectively. | ||
| M2045 | CEP-32496 | Raf |
| RXDX-105; Agerafenib | ||
| CEP-32496 is a potent orally active BRAF inhibitor with IC50 of 14 nM. | ||
| M3026 | Sorafenib (BAY 43-9006) | Raf |
| BAY 43-9006 | ||
| Sorafenib (BAY 43-9006) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively. Sorafenib is a multikinase inhibitor with IC50 values of 15 nM, 20 nM, 57 nM and 58 nM for VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib is a ferroptosis activator. | ||
| M3196 | CCT239065 | DNA/RNA Synthesis |
| CCT239065 is a novel and selective BRAFV600E and LCK inhibitor with IC50 of 13 nM and 6 nM, respectively. | ||
| M10731 | ICCB-19 hydrochloride | Autophagy |
| ICCB-19 hydrochloride is a TRADD (TNFRSF1A associated via death domain) inhibitor. ICCB-19 hydrochloride binds to the N-terminal domain of TRADD (TRADD-N), breaking its binding to TRADD-C and TRAF2. ICCB-19 hydrochloride is an indirect inhibitor of RIPK1 kinase activity. ICCB-19 hydrochloride effectively induces autophagy and degradation of long-lived proteins. | ||
| M13561 | C25-140 | TNF Receptor |
| C25-140, a first-in-class, orally active, and fairly selective TRAF6-Ubc13 inhibitor, directly binds to TRAF6, and blocks the interaction of TRAF6 with Ubc13. C25-140 lowers TRAF6 activity, reduces NF-κB activation, and combats autoimmunity. | ||
| M14181 | LY3009120 | Raf |
| DP-4978 | ||
| LY3009120 (DP-4978) is a pan RAF inhibitor which inhibits BRAFV600E, BRAFWT and CRAFWT with IC50s of 5.8, 9.1 and 15 nM, respectively. | ||
| M20678 | Belvarafenib | Raf |
| GDC5573; HM95573; RG6185 | ||
| Belvarafenib (GDC5573, HM95573, RG6185) is a selective and orally bioavailable pan-RAF kinase inhibitor with IC50 values of 41 nM, 7 nM and 2 nM for BRAF WT, BRAF(V600E) and CRAF kinases, respectively. | ||
| M21146 | LUT014 | Raf |
| LUT014, a B-Raf inhibitor with an IC50 value of 11.7 nM, was developed for the study of reducing acne-like lesions associated with EGFR inhibitors at restricted doses. | ||
| M21513 | Vemurafenib-d7 | Raf |
| PLX4032-d7; RG7204-d7; RO5185426-d7 | ||
| Vemurafenib (PLX4032; RG7204; RO5185426) is a first-in-class selective B-RAF inhibitor that inhibits the activity of RAFV600E and c-RAF-1 with IC50 at 31 nM and 48 nM, respectively. Vemurafenib can induce autophagy. | ||
| M21520 | Vemurafenib-d5 | Raf |
| Vemurafenib (PLX4032; RG7204; RO5185426) is a first-in-class selective B-RAF inhibitor that inhibits the activity of RAFV600E and c-RAF-1 with IC50 at 31 nM and 48 nM, respectively. | ||
| M27818 | Takeda-6D | Raf |
| Takeda-6D (compound 6d) is an orally active and potent BRAF/VEGFR2 inhibitor, with IC50 values of 7.0 and 2.2 nM, respectively. Takeda-6D shows antiangiogenesis by suppressing the VEGFR2 pathway in 293/KDR and VEGF-stimulated HUVEC cells.Takeda-6D shows significant suppression of ERK1/2 phosphorylation. Takeda-6D shows antitumor activity. | ||
| M29356 | Raf inhibitor 2 | Raf |
| Raf inhibitor 2 is a potent raf kinase (IC50<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research. | ||
| M30907 | B-Raf IN 11 | Raf |
| B-Raf IN 11 (ZINC72115182) is a selective B-RafV600E inhibitor (IC50=76 nM), shows selectivity for B-RafV600E over B-RafWT with selectivity of 3.1-fold. B-Raf IN 11 can be used in colorectal cancer research[1] | ||
| M39216 | Cudraflavone B | NF-κB |
| Cudraflavone B is a prenylated flavonoid with anti-inflammatory and anti-tumor properties. Cudraflavone B is also a dual inhibitor of COX-1 and COX-2. Cudraflavone B blocks the translocation of nuclear factor κB (NF-κB) from the cytoplasm to the nucleus in macrophages. | ||
| M57288 | Sorafenib-d3 | Raf |
| Donafenib; Bay 43-9006-d3 | ||
| Sorafenib-d3 (Donafenib) is a deuterium-labeled Sorafenib, it is the first deuterium-generation tumor suppressor small molecule. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
